The targeted therapy of the patient with pulmonary metastases of colorectal cancer in a the sequence of bevacizumab‑panitumumab‑regorafenib

01/2019

MUDr. Sabina Svobodová¹; MUDr. Adam Peštál, Ph.D.²; MUDr. Igor Suškevič³

¹ Onkologicko-chirurgické oddělení FN u svaté Anny, Brno

² 1. chirurgická klinika LF MU a FN u svaté Anny, Brno

³ Klinika zobrazovacích metod LF MU a FN u svaté Anny, Brno

SUMMARY

In the course of the disease more than half of the patients with colorectal cancer creates metastases to distant organs. The liver is the first site of metastases in 80 %, followed by the lungs. The basis of the system of treatment of metastatic colorectal cancer is chemotherapy. This targeted therapy increases its beneficence. An important therapeutic modality is surgical resection of metastases, which has the potential to improve overall survival, which today exceeds 30 months. The case report demonstrates that suitably elected treatment can achieve a multimodal overall survival of the patient and a good quality of life even in the metastatic stage of oncological disease approximately in years. It shows the current options for the targeted treatment of metastatic colorectal cancer. It confirms the long-term efficacy of the targeted treatment, maintaining good effect while applying a sequence of VEGF antibodies against anti EGFR inhibitor.

KEY WORDS

colorectal cancer, pulmonary metastases, targeted therapy, sequential therapy, bevacizumab, panitumumab, regorafenib